Downloads
Abstract
Background: Most EGFR mutations in non-small cell lung cancer (NSCLC) are Del19 and L858R, with other uncommon mutations comprising only about 10%-20%. Afatinib, a second-generation tyrosine kinase inhibitor, approved for treating advance - stage NSCLC with uncommon EGFR mutations. Further real-world studies are needed to evaluate
the effectiveness of this treatment indication in Vietnam.
Method: 58 patients diagnosed with stage IIIC - IV (AJCC 8th edition) NSCLC, Adenocarcinoma subtype, with uncommon EGFR mutations at K Hospital from January 2018 to December 2023, followed up until May 2024
Results: Single mutations accounted for 63.8% while compound mutations accounted for 36.2%. The objective response rate was 62%, and disease control rate was 84.4%. There was no difference in response rate or disease controbetween the single mutation group and the compound mutation group. The median progression-free survival (mPFS) for the study group was 11.8 ± 1.3 months. The median PFS in the single mutation group was significantly shorter compared to the compound mutation group, at 10.3 ± 2.7 months and 14.2 ± 1.8 months, respectively (p = 0.008).
Conclusion: Afatinib as first-line treatment shows good efficacy in terms of response, disease control, and median progression-free survival (mPFS) in Vietnamese patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
Keywords: Afatinib, non-small cell lung cancer, advanced stage, EGFR, uncommon mutation.
References
Goodman GP, Engh CA, Goyal N. Revision total hip
arthroplasty exposure considerations: Which way in?
Seminars in Arthroplasty. 2015;26(3):150-155.
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS,
Schuler M, et al. Clinical activity of afatinib in patients
with advanced non-small-cell lung cancer harbouring
uncommon EGFR mutations: a combined post-hoc analysis
of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet
Oncol. 2015;16(7):830-8.
Dungo RT, Keating GM. Afatinib: first global approval.
Drugs. 2013;73:1503-1515.
Hirsch FR, Varella-Garcia M, Bunn Jr PA, Di Maria MV,
Veve R, Bremnes RM, et al. Epidermal growth factor
receptor in non–small-cell lung carcinomas: correlation
between gene copy number and protein expression
and impact on prognosis. Journal of clinical oncology.
;21(20):3798-3807.
Borgeaud M, Parikh K, Banna GL, Kim F, Olivier T, Le
X, et al. Unveiling the Landscape of uncommon EGFR
Mutations in Non-Small Cell Lung Cancer-A Systematic
Review. Journal of Thoracic Oncology. 2024.
Hsu P-C, Lee S-H, Chiu L-C, Lee C-S, Wu C-E, Kuo
SC-H, et al. Afatinib in untreated stage IIIB/IV lung
adenocarcinoma with major uncommon epidermal growth
factor receptor (EGFR) mutations (G719X/L861Q/S768I):
a multicenter observational study in Taiwan. Targeted
Oncology. 2023;18(2):195-207.
Thanh VH, Hòa NTT. KẾT QUẢ ĐIỀU TRỊ AFATINIB
BƯỚC 1 TRÊN UNG THƯ PHỔI KHÔNG TẾ BÀO
NHỎ, GIAI ĐOẠN TIẾN XA, LOẠI BIỂU MÔ TUYẾN,
CÓ ĐỘT BIẾN HIẾM GẶP CỦA GEN EGFR TẠI BỆNH
VIỆN K.
Pham VL, Le TA, Pham CP, Hoa Nguyen TT, Do AT,
Nguyen TK, et al. Real-world analysis of afatinib as a
first-line treatment for patients with advanced stage nonsmall-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam. Therapeutic Advances in
Medical Oncology. 2024;16:17588359241242972.
Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman
A, Velthaus-Rusik J-L, et al. Treatment outcome of atypical
EGFR mutations in the German national network genomic
medicine lung cancer (nNGM). Annals of oncology.
;33(6):602-615.
Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC,
Chen WC, et al. Comparing the effects of afatinib with
gefitinib or Erlotinib in patients with advanced-stage lung
adenocarcinoma harboring non-classical epidermal growth
factor receptor mutations. Lung Cancer. 2017;110:56-62.
Tu C-Y, Chen C-M, Liao W-C, Wu B-R, Chen C-Y, Chen
W-C, et al. Comparison of the effects of the three major
tyrosine kinase inhibitors as first-line therapy for nonsmall-cell lung cancer harboring epidermal growth factor
receptor mutations. Oncotarget. 2018;9(36):24237.
Yang JC-H, Schuler M, Popat S, Miura S, Heeke S, Park
K, et al. Afatinib for the treatment of NSCLC harboring
uncommon EGFR mutations: a database of 693 cases.
Journal of Thoracic Oncology. 2020;15(5):803-815.
Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N,
Mok T, et al. First-line afatinib versus chemotherapy in
patients with non–small cell lung cancer and common
epidermal growth factor receptor gene mutations
and brain metastases. Journal of Thoracic Oncology.
;11(3):380-390.
Kang L, Mai J, Liang W, Zou Q, Huang C, Lin Y, et al.
CNS efficacy of afatinib as first-line treatment in advanced
non-small cell lung cancer patients with EGFR mutations.
Frontiers in Oncology. 2023;13:1094195.
Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T,
Chewaskulyong B, Lee KH, et al. Osimertinib in untreated
EGFR-mutated advanced non–small-cell lung cancer. New
England journal of medicine. 2018;378(2):113-125.
Okuma Y, Kubota K, Shimokawa M, Hashimoto K,
Kawashima Y, Sakamoto T, et al. First-line osimertinib for
previously untreated patients with NSCLC and uncommon
EGFR mutations: the UNICORN phase 2 nonrandomized
clinical trial. JAMA oncology. 2024;10(1):43-51.
| Published | 30-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 6 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.6.3 | |
| Keywords | Từ khóa: Afatinib, Ung thư phổi không tế bào nhỏ, giai đoạn tiến xa, EGFR, đột biến hiếm |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital